BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20260926T025325EDT-8640ZHRjDf@132.216.98.100
DTSTAMP:20260926T065325Z
DESCRIPTION:Bohdana Ratitch\, PhD Scientific Advisor\, Data Mining & Statis
 tical Analysis\, Advisory Analytics Group - Quintiles IMS Current trends a
 nd open questions in dealing with treatment non-adherence and missing data
  in the clinical trials regulatory environment Tuesday\, 21 February 2017 
 3:30 pm – 4:30 pm - Purvis Hall\, 1020 Pine Ave. West\, Room 24\n\nALL ARE
  WELCOME\n\nAbstract: In recent years\, members of the clinical research c
 ommunity have been promoting the use of estimands as a way to link high-le
 vel clinical trial objectives to analysis strategies\, while providing a c
 lear pre-specification of how non-adherence to randomized treatment\, e.g.
 \, early discontinuation or initiation of rescue therapy\, will be account
 ed for in the estimate of treatment effect. In practice\, even with well-d
 efined estimands and well-designed trials\, some amount of missing data ca
 n be expected\, or it may be impossible to obtain usable (non-confounded) 
 data for a specific estimand for some subjects during the periods of non-a
 dherence. This presentation will review missing data treatment in light of
  the current regulatory landscape. We will discuss the evolution of thinki
 ng regarding what constitutes a useful estimand for different decision mak
 ers\, usability of data during treatment non-adherence\, some common analy
 sis strategies\, and open questions. \n\nSEE PDF FOR DETAILS\n
DTSTART:20170221T203000Z
DTEND:20170221T213000Z
SUMMARY:SEMINAR: 	Current trends and open questions in dealing with treatmen
 t non-adherence and missing data in the clinical trials regulatory environ
 ment
URL:https://www.mcgill.ca/epi-biostat-occh/channels/event/seminar-current-t
 rends-and-open-questions-dealing-treatment-non-adherence-and-missing-data-
 clinical-265535
END:VEVENT
END:VCALENDAR
